My wild guess is that that the problems arose with the Prurisol CRO (cost increases, delays, etc.) whatever they may have been. A B-OM deal with 10M-20M upfront wouldn't have given us enough money to pay the CRO and advance anything else in the pipeline and stop the dilution machine. Including B for IBD indications likely allows the upfront to be 50M-100M+ which gives IPIX money for a couple years of operating expenses plus some trial advancement. Milestone payments from this deal will hopefully carry us to royalties without additional dilution.

I have been a proponent of the largest deal possible (preferred a buyout) and I am pleased to see the larger deal size. I hope this deal will be enough to get us uplisted and lock in the share count. Additionally, I think it's paramount that we get every share in the green ($5/share) as soon as possible even if it means giving up rights years down the line. Now that we're not doing a full buyout, I'm hoping we lock in a second deal on B or P (if results are good) ASAP. A high probability $5-10 is much preferable to an uncertain $50.